Dr. Reddy’s Laboratories has achieved a significant milestone by securing a Notice of Compliance from Health Canada for its generic Semaglutide injection. File photo: Special Arrangement Dr. Reddy’s Laboratories has received a Notice of Compliance (NOC) from Health Canada for its generic Semaglutide Injection. It has become the first company to receive the market authorisation for generic Semaglutide Injection in Canada, ahead of Health Canada’s review target date. The authorisation covers the 2 mg/pen (1.34 mg/mL) and 4 mg/pen (1.34 mg/mL). Canada is recognised as the world’s second-largest market for Semaglutide, Dr. Reddy’s said, citing IQVIA MAT Q3 2025 numbers. Published – April 29, 2026 12:48 pm IST Share this: Click to share on WhatsApp (Opens in new window) WhatsApp Click to share on Facebook (Opens in new window) Facebook Click to share on Threads (Opens in new window) Threads Click to share on X (Opens in new window) X Click to share on Telegram (Opens in new window) Telegram Click to share on LinkedIn (Opens in new window) LinkedIn Click to share on Pinterest (Opens in new window) Pinterest Click to email a link to a friend (Opens in new window) Email More Click to print (Opens in new window) Print Click to share on Reddit (Opens in new window) Reddit Click to share on Tumblr (Opens in new window) Tumblr Click to share on Pocket (Opens in new window) Pocket Click to share on Mastodon (Opens in new window) Mastodon Click to share on Nextdoor (Opens in new window) Nextdoor Click to share on Bluesky (Opens in new window) Bluesky Like this:Like Loading... Post navigation Why India must rethink alternative schooling pathways Bong Joon Ho reunites with Neon for first animated feature ‘Ally’, set for 2027 release